Review
doi: 10.1016/j.gtc.2006.09.006.
Infusion reactions and their management
Affiliations
- PMID: 17129817
- DOI: 10.1016/j.gtc.2006.09.006
Item in Clipboard
Review
Infusion reactions and their management
Gastroenterol Clin North Am.
2006 Dec.
Abstract
Infliximab therapy should be optimized to minimize immunogenicity, to prevent infusion reactions, and to maintain clinical response. Based on best available evidence, strategies include minimizing the formation of ATI by administering infliximab as a multidose induction therapy followed by scheduled maintenance regiment, the use of concurrent immunomodulators, and possibly premedicating with steroids. Infusion reaction are common and they can be managed using specific protocols outlined in this article.
Similar articles
-
Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.Gastroenterology. 2003 Apr;124(4):917-24. doi: 10.1053/gast.2003.50145. Gastroenterology. 2003. PMID: 12671888 Clinical Trial.
-
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.Gastroenterology. 2007 Mar;132(3):863-73; quiz 1165-6. doi: 10.1053/j.gastro.2006.12.003. Epub 2006 Dec 3. Gastroenterology. 2007. PMID: 17324398 Clinical Trial.
-
Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions.Aliment Pharmacol Ther. 2006 Sep 1;24(5):851-8. doi: 10.1111/j.1365-2036.2006.03026.x. Aliment Pharmacol Ther. 2006. PMID: 16918890
-
Guidelines for treatment with infliximab for Crohn's disease.Neth J Med. 2006 Jul-Aug;64(7):219-29. Neth J Med. 2006. PMID: 16929083 Review.
-
Infliximab therapy in children and adolescents with inflammatory bowel disease.Drugs. 2007;67(12):1703-23. doi: 10.2165/00003495-200767120-00005. Drugs. 2007. PMID: 17683171 Review.
Cited by
-
Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management.Br J Pharmacol. 2015 Nov;172(21):5025-36. doi: 10.1111/bph.13268. Epub 2015 Oct 25. Br J Pharmacol. 2015. PMID: 26265306 Free PMC article. Review.
-
Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease.Expert Rev Clin Immunol. 2010 Jul;6(4):607-20. doi: 10.1586/eci.10.45. Expert Rev Clin Immunol. 2010. PMID: 20594134 Free PMC article. Review.
-
Managing Crohn disease in children and adolescents : focus on tumor necrosis factor antagonists.Paediatr Drugs. 2008;10(1):31-8. doi: 10.2165/00148581-200810010-00004. Paediatr Drugs. 2008. PMID: 18162006 Review.
-
Synthetically mannosylated antigens induce antigen-specific humoral tolerance and reduce anti-drug antibody responses to immunogenic biologics.Cell Rep Med. 2024 Jan 16;5(1):101345. doi: 10.1016/j.xcrm.2023.101345. Epub 2023 Dec 20. Cell Rep Med. 2024. PMID: 38128533 Free PMC article.
-
Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations.AAPS J. 2014 Jul;16(4):658-73. doi: 10.1208/s12248-014-9599-2. Epub 2014 Apr 24. AAPS J. 2014. PMID: 24764037 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
